2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride | 1229-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 英文名称: 2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride
• 英文别名: Chlorprothixene hydrochloride；Chlorprothixenhydrochlorid；chlorprothixene HCl；chlorprothixene hydrochloride；[3-((E)-2-chloro-thioxanthen-9-ylidene)-propyl]-dimethyl-amine; hydrochloride；[3-((Z)-2-chloro-thioxanthen-9-ylidene)-propyl]-dimethyl-amine; hydrochloride；3-(2-chlorothioxanthen-9-ylidene)propyl-dimethylazanium;chloride
• CAS: 1229-38-5
• 化学式: C₁₈H₁₈ClNS*ClH
• 分子量: 352.328
• InChiKey: YWKRLOSRDGPEJR-UHFFFAOYSA-N

物化性质

• 熔点：
  189-190 °C

计算性质

• 辛醇/水分配系数(LogP)：
  5.61
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  28.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride 在 potassium permanganate 作用下， 以 水 为溶剂， 生成 2-氯噻吨酮
  参考文献：
  名称：

  Oxidation of chlorprothixene with potassium permanganate

  摘要：

  DOI：

  10.1111/j.2042-7158.1980.tb12988.x

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Small molecule toll-like receptor (TLR) antagonists
  申请人：Lipford B. Grayson

  公开号：US20050119273A1

  公开（公告）日：2005-06-02

  The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

  本发明提供了用于调节通过Toll样受体信号传导的方法和组合物。该方法涉及使用含有至少两个环的核心结构的小分子与表达TLR的细胞接触。其中某些化合物是4-主氨基喹啉。许多化合物和方法特别适用于抑制涉及至少一个TLR9、TLR8、TLR7和TLR3的免疫刺激。该方法可用于治疗自身免疫、炎症、过敏、哮喘、移植排斥、移植物抗宿主病、感染、败血症、癌症和免疫缺陷。
• METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS
  申请人：Mootha Vamsi K.

  公开号：US20120136007A1

  公开（公告）日：2012-05-31

  Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.

  模型系统表明，将细胞从氧化磷酸化（OXPHOS）转向糖酵解可以保护细胞免受死亡的影响。然而，利用这种策略的治疗潜力受到了缺乏临床安全制剂来重塑能量代谢的限制。本发明确定了能够调节氧化代谢的非毒性小分子（例如药物类化合物）。其中一种已确定的化合物包括美克林。如本文所述，美克林及其对映体S-美克林将OXPHOS重定向到糖酵解。这样的化合物可以在退行性疾病（如糖尿病、亨廷顿病、帕金森病和阿尔茨海默病）以及缺血性疾病（包括但不限于中风、心脏病发作或再灌注损伤）中具有保护或治疗作用。
• A sustained-release preparation and production thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0294103A1

  公开（公告）日：1988-12-07

  The present invention concerns a sustained-release microcapsule preparation comprising an ion exchange resin with 6 to 16% crosslinking, containing a drug adsorbed to not less than 80% of its theoretical ion adsorption amount and coated with a water-permeable polymer. The sustained-release preparation of this invention contains a high concentration of an absorbed drug: it shows neither cracking nor breaking in its coat and exhibits good sustained-release properties which enhance its dosage form design and makes it easy to take.

  本发明涉及一种缓释微胶囊制剂，该制剂由交联度为 6% 至 16% 的离子交换树脂构成，其中含有吸附量不低于理论离子吸附量 80% 的药物，并包覆有透水性聚合物。 本发明的缓释制剂含有高浓度的吸附药物：其包覆层既不会开裂，也不会破损，并且具有良好的缓释特性，从而增强了其剂型设计，使其易于服用。
• Skin penetration system for salts of amine-functional drugs
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0351897A2

  公开（公告）日：1990-01-24

  The invention involves pharmaceutical compositions for topical application comprising: (a) a pharmaceutically-acceptable salt of addition of an amine-functional drug (other than opioid analgesic drugs); (b) a C₇ to C₂₂ straight-chain or branched-chain, saturated or unsaturated, fatty acid having a melting point of less than about 50°C; and (c) a C₃-C₄ alkane diol.

  本发明涉及用于局部应用的药物组合物，包括 (a) 一种胺功能药物（阿片类镇痛药除外）的药学上可接受的加成盐； (b) C₇ 至 C₂₂ 直链或支链、饱和或不饱和脂肪酸，熔点低于约 50°C；以及 (c) C₃-C₄ 烷二醇。